Table 2.
Cluster names and topics withinclusters
| Cluster name | Latent dirichlet allocation topics |
|---|---|
| 2017–2018 | |
| Examination and care of heart failure | Care and readmission of patients with heart failure |
| Imaging—ultrasound, and MRI | |
| Methods of monitoring disease conditions | |
| Related care, palliative care, and quality of life in patients with heart failure | |
| Heart failure and arrhythmias | Cardiac resynchronization therapy for heart failure |
| Pacing therapy for arrhythmias | |
| Coagulation, anticoagulation, and atrial fibrillation | |
| Biomarkers, prediction in risk heart factors, failure and prognosis | The role of NT-proBNP in the diagnosis and treatment of heart failure |
| Heart failure and serum proteins | |
| Renin–angiotensin–aldosterone system | |
| Biomarkers and predictive models of heart failure | |
| Risk score and stratification of heart failure | |
| Heart arteries failure and lesions of coronary | Coronary artery lesions and heart failure |
| Acute coronary syndrome and myocardial injury | |
| Acute myocardial infarction—interventional and pharmacological treatment | |
| Interaction of heart failure with other organ lesions | Treatment of the cardiorenal syndrome |
| Heart failure and respiratory sleep disorders | |
| Pulmonary hypertension and heart failure | |
| Heart failure and thyroid function | |
| Heart failure and liver dysfunction | |
| Treatment devices of heart failure—cardiac assist | Treatment of heart failure—ventricular assist device |
| Extracorporeal membrane oxygenation therapy | |
| Minimally invasive surgery and assistive devices | |
| Drug treatment of heart failure | Mechanism and application of antagonist drugs |
| Vasoactive drugs and the treatment of heart failure | |
| Potassium metabolism and cardiotonic drugs—effects on patients with heart failure | |
| Cardiovascular effects of blood glucose control drugs | |
| Chronic failure and disease metabolic management abnormalities of heart | Water–electrolyte balance and micronutrient supplementation in patients with heart failure |
| Oxygen metabolism and heart failure | |
| Diabetes and heart failure | |
| Effect of obesity and lipids on heart failure | |
| 2020–2021 | |
| Genes, stem cells, and signal transduction | Cell regeneration and signaling pathways |
| Stem cells, genetics, and gene editing | |
| Cells and extracellular matrix | |
| Cardiomyocyte ultrastructure, energy metabolism, and signaling | |
| Genetics and single nucleotide polymorphisms | |
| Socioeconomics and health policy | Health economics of the treatment and care of heart failure |
| Cost and use of health-care services related to heart failure | |
| Public health, socioeconomics, and digital health | |
| Factors failure and influencing patient education the prognosis of heart | Heart failure after myocardial infarction—treatment and prognosis |
| Psychosocial care for patients with heart failure | |
| The role of exercise in the diagnosis and rehabilitation of heart failure | |
| Effect of ejection fraction on the treatment and prognosis of patients with heart failure | |
| Valvular lesions—Interventional treatment | Minimally invasive treatment of heart failure—transcatheter valve replacement |
| Treatment of mitral valve lesions—surgical and interventional | |
| Minimally invasive surgery and assistive devices | |
| Minimally invasive treatment for heart failure—TAVR | |
| Treatment of heart failure—drugs, surgery, and cardiac assist devices | ECMO therapy |
| Emergency treatment of heart failure | |
| Heart transplant | |
| Medications for heart failure | |
| Care telemedicine for heart failure, smart medicine, and | Related care, palliative care, and quality of life in patients with heart failure |
| Care and patient education in heart failure | |
| Research on artificial intelligence and heart failure | |
| Remote and home monitoring of heart failure | |
| Precision medicine and telemedicine | |
| COVID-19 and heart failure | COVID-19 and heart failure |
| Risk support factors tools for heart failure and decision | Biomarkers and predictive models of heart failure |
| Effect of obesity and lipids on heart failure | |
| Impact of environmental factors on cardiovascular health | |
| Changes in the cardiovascular system during aging |
MRI: Magnetic resonance imaging; TAVR: Transcatheteraortic valve replacement; ECMO: Extracorporeal membrane oxygenation; COVID-19: corona virusdisease 2019.